New drug camoteskimab tested for Tough-to-Treat eczema

NCT ID NCT06436183

Disease control Sponsor: Apollo Therapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new drug, camoteskimab, in 62 adults with moderate to severe eczema (atopic dermatitis). Participants received either the drug or a placebo for 16 weeks, followed by an open-label extension where everyone could get the drug. The main goal was to see if camoteskimab reduces eczema severity, measured by the EASI score. The trial is complete, and results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: camoteskimab (a drug given by injection)
What this could lead to: If it works, this could point toward a new treatment option for people with moderate to severe eczema.
What could go wrong: This is an early phase 2a trial with only 62 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

62 people

The number who actually took part.

Started

May 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants must be 18-75 years of age inclusive, at the time of signing the informed consent. 2. Chronic AD for at least 1 year. 3. Participants with moderate to severe AD defined by: 1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Baseline. 2. AD involvement of ≥ 10% body surface area (BSA) at Baseline. 3. EASI score of ≥ 12 at Baseline. 4. Pruritus numerical rating scale (NRS) ≥ 4 at Baseline. 4. Participants who are candidates for systemic therapy, defined as inadequate response to treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable. 5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants: * Sexually active females of childbearing potential must agree to use two forms of accepted methods of highly effective forms of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes: * IUD plus one barrier method. * Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method. * 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or * A vasectomized partner\*. Male participants: * Sexually active male participants and males and who are partners of females of childbearing potential agree to use two forms of contraception as above and to not donate sperm or try to conceive during the treatment period and for at least 3 months after the last dose of study drug. 6. Participant provides signed informed consent. Exclusion Criteria: 1. Participant has history of use of more than two (2) prior systemic therapies for AD (e.g. biologics or JAKi) and who used any of these medications as follows: 1. Dupilumab, tralokinumab, lebrikizumab within 8 weeks prior to Baseline. 2. Systemic JAKi within 4 weeks prior to Baseline. 3. TCS, TCI, topical phosphodiesterase-4 (PDE4) inhibitors, and topical JAKi within 7 days prior to enrollment (at Baseline) or more than five half-lives whichever is longer. 2. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments. 3. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma). 4. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12- lead ECG as considered by the perfusion index that may interfere with the interpretation of QTc interval changes. 5. Participant has AD involving ocular symptoms, or blepharitis, conjunctivitis, or keratitis diagnosed within the last 60 days prior to the screening visit, requiring chronic ocular corticosteroid treatment. 6. Participant has severe or uncontrolled seasonal or allergic rhinitis, asthma or any other non-AD disease as judged by the Investigator. Participants with seasonal or allergic rhinitis, asthma or any other non-AD disease requiring use of intranasal or inhaled corticosteroid that is stable and well-controlled are not excluded. 7. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test; Active hepatitis B virus (HBV): confirmed hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+); Active hepatitis C virus (HCV): Confirmed hepatitis C antibody positive (+); evidence of active or latent TB 8. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of * Completely resected basal call or squamous cell carcinoma of the skin. * Carcinoma in situ of the cervix. 9. Has had previous exposure to anti-IL-18 therapy. 10. Treatment with any investigational agent, or any investigational device or procedure, within 28 days (or 5 half- lives, whichever is greater) of screening. 11. Has any of the following laboratory findings 1. Glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2. 2. Hemoglobin ≤8 g/dL. 3. Neutrophils ≤1,500/μL. 4. Platelets ≤75,000/μL.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema atopic IgE-mediated allergic disorder dermatitis Eczema skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC Atopic dermatitis Dermatitis Dermatologic disease Eczema Eczema atopic dermatitis Eczema, atopic

Contacts and locations

Locations

Advanced Dermatology and Skin Cancer Center - Saint Joseph

Saint Joseph, Missouri, 64506, United States
Amicis Research Center (Northridge)

Northridge, California, 91324, United States
Avita Clinical Research - Dermatology

Tampa, Florida, 33613, United States
California Allergy and Asthma Medical Group

Los Angeles, California, 90025, United States
California Dermatology & Clinical Research Institute

Encinitas, California, 92024, United States
Center for Clinical Studies

Houston, Texas, 77004, United States
Center for Dermatology Clinical Research, Inc.

Fremont, California, 94538, United States
Central Sooner Research

Oklahoma City, Oklahoma, 73071, United States
Clinical Sciences Institute

Santa Monica, California, 90404, United States
Clinical Trial Network

Houston, Texas, 77074, United States
Clinique Dermatologique de Sherbrooke

Sherbrooke, Quebec, J1G 1X9, Canada
Clinique Medicale Saint-Louis

Québec, Quebec, G1W 4R4, Canada
Cura Clinical Research

Oxnard, California, 93030, United States
D&H National Research Centers, Inc.

Miami, Florida, 33155, United States
Dawes Fretzin Clinical Research

Indianapolis, Indiana, 46250, United States
First OC Dermatology Research, Inc.

Fountain Valley, California, 92708, United States
Kingsway Clinical Research

Etobicoke, Ontario, M8X 1Y9, Canada
M3 Wake Research, Inc.

Raleigh, North Carolina, 27612, United States
Medical Dermatology Specialists, PC/US Dermatology Partners

Phoenix, Arizona, 85006, United States
Michigan Dermatology Institute

Waterford, Michigan, 28329, United States
ObjectiveHealth-The Skin Surgery Center for Clinical Research

Winston-Salem, North Carolina, 27103, United States
Owensboro Dermatology Associates

Owensboro, Kentucky, 42303, United States
Paddington Testing Co. Inc

Philadelphia, Pennsylvania, 19103, United States
Rejuvenation Dermatology Clinic Edmonton South

Edmonton, Alberta, T6W 0J5, Canada
Renaissance Research and Medical Group

Cape Coral, Florida, 33991, United States
Revival Research Institute

Troy, Michigan, 48084, United States
Rodgers Dermatology

Frisco, Texas, 75034, United States
Skin Sciences, PLLC

Louisville, Kentucky, 40217, United States
Skin Specialists PC

Omaha, Nebraska, 68144, United States
Sneeze, Wheeze & Itch Associates, LLC

Normal, Illinois, 61761, United States
Somerset Skin Centre

Troy, Michigan, 48084, United States
Unity Clinical Research - Dermatology

Oklahoma City, Oklahoma, 73118, United States
University of California Los Angeles Dermatology

Los Angeles, California, 90095, United States
VASDHS - Veterans Affairs San Diego Medical Center

San Diego, California, 92161, United States
Youthful Image

Edmonton, Alberta, T5J 3S9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.